Kimberly-Clark Corporation (FRA:KMY)
| Market Cap | 29.61B |
| Revenue (ttm) | 16.81B |
| Net Income (ttm) | 1.68B |
| Shares Out | n/a |
| EPS (ttm) | 5.04 |
| PE Ratio | 17.65 |
| Forward PE | 13.38 |
| Dividend | 4.50 (5.02%) |
| Ex-Dividend Date | Sep 5, 2025 |
| Volume | 237 |
| Average Volume | 179 |
| Open | 89.51 |
| Previous Close | 88.59 |
| Day's Range | 89.42 - 89.51 |
| 52-Week Range | 86.97 - 136.66 |
| Beta | n/a |
| RSI | 28.41 |
| Earnings Date | Oct 30, 2025 |
About Kimberly-Clark
Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care products in the United States. It operates through three segments: North America, International Personal Care, and International Family Care and Professional. The company North America segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers, and other related produc... [Read more]
Financial Performance
In 2024, Kimberly-Clark's revenue was $20.06 billion, a decrease of -1.83% compared to the previous year's $20.43 billion. Earnings were $2.55 billion, an increase of 44.27%.
Financial numbers in USD Financial StatementsNews
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Kimberly-Clark Corporation (NASDAQ: KMB)
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and ...
Watch These Stocks Falling 10% Or More
Fiserv (FI) leads decliners with a 49% drop, driven by leadership turmoil, weak consumer spending, and a downgraded quant rating to 'Strong Sell.' Alexandria Real Estate (ARE) and Robert Half (RHI) su...
What Could Stop Kimberly-Clark’s Deal for Kenvue
Kenvue's $48.7 Billion Sale Puts Consumer Staples ETFs Back In Vogue
Consumer staples ETFs, usually the quiet corner of the market, are suddenly in the spotlight. The $48.7 billion acquisition of Kenvue Inc. (NYSE:KVUE) by Kimberly-Clark Corp (NASDAQ:KMB) has stirred r...
Analyst Robert Moskow Lowers Price Target for Kimberly-Clark (KMB) | KMB Stock News
Analyst Robert Moskow Lowers Price Target for Kimberly-Clark (KMB) | KMB Stock News
KMB: Morgan Stanley Lowers Price Target on Kimberly-Clark | KMB Stock News
KMB: Morgan Stanley Lowers Price Target on Kimberly-Clark | KMB Stock News
3 Dividend Stocks for November 2025
This month's trio includes two ADRs.
Kimberly-Clark (KMB) Shares Dip Following Acquisition Announcement
Kimberly-Clark (KMB) Shares Dip Following Acquisition Announcement
Congressional Trading Report: Sen. Sheldon Whitehouse Sold Over $30K In Progressive Stock
November 3, 2025 records indicate that Senator Sheldon Whitehouse filed a sale of Progressive (NYSE: PGR), valued between $30,002 and $100,000. According to the November filing, the transaction occur...
Kimberly-Clark: Can The Kenvue Acquisition Erase The Decade Of Disappointment?
This Kimberly-Clark Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Full story available on Benzinga.com
Tylenol to join Kleenex, Huggies and Listerine in $48.7 billion takeover deal between Kimberly-Clark and Kenvue
Shareholders of Kimberly-Clark will own about 54% of the combined company.
Evercore ISI Downgrade: Kimberly-Clark (KMB) Target Price Lowered to $120 | KMB Stock News
Evercore ISI Downgrade: Kimberly-Clark (KMB) Target Price Lowered to $120 | KMB Stock News
These 2 Dividend Kings Are Combining in a $48.7 Billion Megadeal. Is It A Win-Win for Dividend Investors?
Kimberly-Clark is creating a consumer health and wellness giant.
The CEO Behind Kimberly-Clark's $40 Billion Gamble on Tylenol Maker
Mike Hsu aims to stoke the consumer company's growth by veering into Kenvue's higher-margin but risky health products.
Palantir, Kimberly-Clark, Hims & Hers, Navitas And Cipher Mining: Why These 5 Stocks Are On Investors' Radars Today
On Monday, major U.S. indexes showed mixed performance — the Dow Jones Industrial Average slipped nearly 0.5% to 47,336.68, while the S&P 500 edged up 0.2% to 6,851.97. The Nasdaq closed 0.46% higher ...
Kimberly-Clark CEO Mike Hsu goes one-on-one with Jim Cramer
Kimberly-Clark Chairman and CEO Mike Hsu joins 'Mad Money' host Jim Cramer to talk the recent acquisition of Kenvue, quarterly results, consumer trends, and more.
Tylenol concerns came out in the middle of our detailed due diligence process, says Kimberly-Clark CEO
Kimberly-Clark Chairman and CEO Mike Hsu joins 'Mad Money' host Jim Cramer to talk the recent acquisition of Kenvue, quarterly results, consumer trends, and more.
Kimberly-Clark CEO Mike Hsu goes one-on-one with Jim Cramer
Kimberly-Clark Chairman and CEO Mike Hsu joins 'Mad Money' host Jim Cramer to talk the recent acquisition of Kenvue, quarterly results, consumer trends, and more.
Kenvue Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kenvue Inc. - KVUE
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...
Kimberly-Clark CEO talks Kenvue acquisition, calls Tylenol brand 'resilient'
Kimberly-Clark CEO Mike Hsu discussed his company's $48.7 billion acquisition of Kenvue in a Monday interview with CNBC's Jim Cramer.
Kenvue's legal risks loom over planned acquisition by Kimberly-Clark
Kimberly-Clark said on Monday it plans to acquire Band-Aid maker Kenvue , even as the latter company faces thousands of lawsuits involving its painkiller Tylenol and talc-based baby powder, raising qu...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kenvue Inc.
NEW YORK , Nov. 3, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kenvue Inc. (NYSE: KVUE) and its board of directors concerning the proposed acquisition ...
Kimberly-Clark Stock Takes Biggest One-Day Hit Since Black Monday
Investor Outlook: Kimberly-Clark’s US$40B Kenvue deal marks new era of transformation
Kimberly-Clark’s US$40B Kenvue deal signals a strategic shift into consumer health and could reshape its position against Unilever and P&G.